摘要
目的探讨血小板活化标志物标志物P-选择素(CD62P)、血小板激活复合物-1(PAC-1)及溶酶体颗粒糖蛋白(CD63)在妊娠期肝内胆汁淤积症(ICP)发生发展中的意义及应用价值。方法选择2016年12月-2018年11月在本院住院的轻度ICP患者50例,重度ICP患者15例,50例正常妊娠者为对照组,应用流式细胞仪检测全血中CD62P、PAC-1的表达水平。另外选择本院轻度ICP患者30例,重度ICP患者15例,46例正常妊娠者为对照组,同法检测CD63的表达水平。结果ICP患者血液循环中的CD62P、PAC-1及CD63表达明显高于正常妊娠组(P<0.05);且重度ICP患者CD62P、PAC-1表达显著高于轻度ICP组(P<0.05),CD63的表达在轻度、重度ICP患者中差异无统计学意义(P>0.05)。结论ICP患者疾病发展中存在明显的血小板活化,PAC-1、CD62P及CD63能反映出血小板活化的状态,且PAC-1和CD62P更能明显地反映血小板活化情况,适合作为辅助指标评估ICP疾病的严重程度,为阻断ICP病变中的血栓形成提供依据。
Objective To explore the significance and application value of platelet activation markers in the development of intrahepatic cholestasis(ICP).Methods Fifty patients with mild ICP who were admitted to our hospital from December 2016 to November 2018,and 15 patients with severe ICP were collected,another 50 normal pregnant women were selected as control group.Flow cytometry was used to detect P-Selectin(CD62 P),platelet activating complex-1(PAC-1)expression level in whole blood.In addition,30 patients with mild ICP,15 patients with severe ICP,and 46 normal pregnant women were selected as the control group,were collected to detect the level of lysosomal granule glycoprotein(CD63)by the same method.Results The levels of CD62 P,PAC-1 and CD63 in the blood circulation of ICP patients were significantly higher than that in the normal pregnancy group(P<0.05).The levels of CD62 P and PAC-1 in patients with severe ICP were significantly higher than that in mild ICP group(P<0.05).The difference in the CD63 level of patients with mild and severe ICP were not statistically significant(P>0.05).Conclusion There is obvious platelet activation in the development of ICP patients.PAC-1,CD62 P and CD63 can reflect the state of platelet activation;PAC-1 and CD62 P are more suitable as indicators for further judging the severity of the disease,which can provide a basis for blocking thrombosis in the development of lesions in ICP patients.
作者
胡丽红
俎德学
刘桂菊
张洁
胡婷婷
HU Li-hong;ZU De-xue;LIU Gui-ju;ZHANG Jie;HU Ting-ting(The Affiliated Hospital of Hangzhou Normal University,Hangzhou,Zhejiang 310015,China)
出处
《中国卫生检验杂志》
CAS
2020年第6期688-691,共4页
Chinese Journal of Health Laboratory Technology
基金
杭州市卫生科技计划项目(2017A15)。